Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Renal Impairment Clear all
Suspended Phase 3 Interventional

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

NCT04523727
View directory record Official record
Conditions
Hyperphosphatemia Related to Chronic Kidney Disease
Interventions
ferric citrate
Drug
Lead sponsor
Keryx Biopharmaceuticals
Industry
Eligibility
6 Years to 16 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 24, 2026, 4:58 PM EDT
Withdrawn Not applicable Interventional

Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study B

NCT03519360
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
UFR-restricted dialysis, UFR-unrestricted dialysis
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
View directory record Official record
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 3 Interventional

A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease

NCT00002397
View directory record Official record
Conditions
HIV Infections, AIDS-Associated Nephropathy
Interventions
Nelfinavir mesylate, Saquinavir, Lamivudine, Stavudine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 24, 2026, 4:58 PM EDT
Completed No phase listed Observational

A Study Using Surveys to Learn More About Treatment With Steroidal Mineralocorticoid Receptor Antagonists, How They Are Used, What Side Effects They Have, and How Satisfied People Who Receive Them Are in the US

NCT05407662
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus, Heart Failure
Interventions
sMRA therapies
Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease

NCT03383627
View directory record Official record
Conditions
Diabetes, Kidney Diseases
Interventions
Continuous Glucose Monitoring
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential.

NCT05505162
View directory record Official record
Conditions
Healthy Female Participants
Interventions
Zibotentan, EE/LNG
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter

NCT02453646
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
NexSite HD Patients
Device
Lead sponsor
Marvao Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
6
States / cities
Greenville, North Carolina • New Bern, North Carolina • Raleigh, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2018 · Synced Jul 24, 2026, 4:58 PM EDT
Recruiting No phase listed Observational

The KidneyCARE (Community Access to Research Equity) Study

NCT05497518
View directory record Official record
Conditions
Chronic Kidney Disease, Dialysis, Kidney Transplant
Interventions
Observational study - registry
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2070
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Comparison Study of Daily Ultrafiltration and Twice-weekly Hemodialysis

NCT00825318
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
Ultrafiltration
Procedure
Lead sponsor
Renal Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Comparing Everolimus and Sirolimus in Renal Transplant Recipients

NCT01976390
View directory record Official record
Conditions
Renal Failure
Interventions
Everolimus, Sirolimus
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

Isoflavones and Acute-phase Response in Chronic Renal Failure

NCT00029796
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
soy isoflavones
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Jul 24, 2026, 4:58 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infusion Investigational Intervention in Participants Aged 35 to 75 Years of Age With Chronic Kidney Disease (CKD)

NCT06721143
View directory record Official record
Conditions
Chronic Kidney Disease Stage 3
Interventions
AION-301, Placebo
Biological · Drug
Lead sponsor
AION Healthspan, Inc.
Industry
Eligibility
35 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 24, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional Results available

The Impact of Pomegranate Extract on Chronic Cardiomyopathy Complicated by Renal Insufficiency (ImPrOVE): a Pilot Study

NCT01102140
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure
Interventions
POMx, pomegranate polyphenol extract, Sugar Pill
Drug
Lead sponsor
Jennifer Cowger , MD, MS
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

NCT03036150
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
4,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
55
States / cities
Birmingham, Alabama • Hawaiian Gardens, California • Lomita, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 2 Interventional

An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)

NCT04987242
View directory record Official record
Conditions
Hyperuricemia, Gout, Chronic Kidney Diseases
Interventions
ALLN-346, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 24, 2026, 4:58 PM EDT
Completed No phase listed Observational

FREEDOM: Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements Study

NCT00288613
View directory record Official record
Conditions
Kidney Failure, Chronic, End Stage Renal Disease, Requiring Dialysis
Interventions
Not listed
Lead sponsor
NxStage Medical
Other
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
41
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Garden Grove, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease

NCT04595370
View directory record Official record
Conditions
Heart Failure, Chronic Kidney Disease
Interventions
AZD9977, Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
21 Years to 130 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
26
States / cities
Beverly Hills, California • Fountain Valley, California • Northridge, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 24, 2026, 4:58 PM EDT
Completed No phase listed Observational

Protein, Nutrition and Cardiovascular Disease in Stage 5 Chronic Kidney Disease

NCT00566670
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
2
States / cities
Nashville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 3 Interventional Results available

The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)

NCT02521181
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lower Dose Sodium Bicarbonate, Higher Dose Sodium Bicarbonate, Placebo
Drug
Lead sponsor
Jennifer Gassman, PhD
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
7
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Jul 24, 2026, 4:58 PM EDT
Enrolling by invitation No phase listed Observational

Feasibility of Intradialytic Monitoring During CKRT

NCT07428395
View directory record Official record
Conditions
Acute Kidney Injury, End Stage Chronic Renal Failure, Dialysis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 24, 2026, 4:58 PM EDT
Completed No phase listed Observational

Dialysis mHealth Survey

NCT04177277
View directory record Official record
Conditions
ESRD
Interventions
Not listed
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Jul 24, 2026, 4:58 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Early Conversion From Tacrolimus to Efalizumab Maintenance Therapy in Kidney Transplant Recipients

NCT00472082
View directory record Official record
Conditions
Kidney Transplantation, Chronic Kidney Failure
Interventions
efalizumab
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 1Phase 2 Interventional Results available

The Effects of Decreasing the Lasix Dose on the Cardiorenal System

NCT00982423
View directory record Official record
Conditions
Heart Failure, Kidney Dysfunction
Interventions
Furosemide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 19, 2015 · Synced Jul 24, 2026, 4:58 PM EDT